Nuvasive Inc (NUVA): Jason Hannon , EVP, International of Nuvasive Inc sold 2,920 shares on Jul 20, 2016. The Insider selling transaction was reported by the company on Jul 22, 2016 to the Securities and Exchange Commission. The shares were sold at $62.80 per share for a total value of $183,376.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 17, 2016, Jason Hannon (EVP, International) sold 14,534 shares at $57.92 per share price.On Jan 7, 2016, Patrick Miles (President and COO) sold 10,723 shares at $54.41 per share price.Also, On Dec 7, 2015, Quentin S. Blackford (CFO and CAO) sold 15,000 shares at $51.10 per share price.On Oct 5, 2015, Matthew Link (President, U.S. Commercial) sold 1,714 shares at $50.72 per share price.
NuVasive: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in NuVasive which led to swings in the share price. The shares opened for trading at $61.52 and hit $62.95 on the upside , eventually ending the session at $62.4, with a gain of 1.86% or 1.14 points. The heightened volatility saw the trading volume jump to 4,89,655 shares. The 52-week high of the share price is $62.95 and the company has a market cap of $3,110 M . The 52-week low of the share price is at $36.81.
Company has been under the radar of several Street Analysts.NuVasive is Upgraded by JP Morgan to Overweight and the brokerage firm has raised the Price Target to $ 74 from a previous price target of $55 .Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Jul 13, 2016.NuVasive is Upgraded by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 63 from a previous price target of $58 .Earlier the firm had a rating of Equal Weight on the company shares. The Rating was issued on May 27, 2016.
Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.